Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (DE:8QQ)
FRANKFURT:8QQ
RESEARCH TOOLSreports
Holding DE:8QQ?
Track your performance easily
8QQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.16 - €5.43
Previous Close€2.61
Volume0.00
Average Volume (3M)1.50K
Market Cap
€767.29M
Enterprise Value€225.05M
Total Cash (Recent Filing)$670.36M
Total Debt (Recent Filing)$79.46M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Feb 25, 2025EPS Estimate
-€0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding294,665,532
10 Day Avg. Volume879
30 Day Avg. Volume1,497
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.67
Price to Sales (P/S)24.16
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.81
Enterprise Value/Gross Profit5.92
Enterprise Value/Ebitda-1.92
Forecast
1Y Price Target
€7.88Price Target Upside202.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
AbCellera Biologics News
PremiumCompany Announcements
AbCellera Biologics Reports Q3 2024 Financial Results
PremiumCompany Announcements
AbCellera Biologics Expands Partnership and Advances Pipeline
PremiumCompany Announcements
AbCellera Biologics Earnings Call and Corporate Presentation UpdateBulls Say, Bears Say
Bulls Say
Clinical DevelopmentManagement confirmed 14 molecules from their pipeline are in the clinic and 95 initiated programs, highlighting active development efforts.
Pipeline DevelopmentThe company continues to make steady progress toward advancing key assets into clinical development.
Strategic PartnershipsABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.
Bears Say
Financial PerformanceAbCellera reported financial results that were below estimates, with a significant EPS miss due to a $32M non-cash R&D impairment charge.
Research And DevelopmentResearch fees are expected to decline as focus shifts to internal pipeline and co-development programs, raising concerns about future revenue stability.
RevenueABCL's quarterly revenue of $6.5M did not meet expectations, with the absence of any milestone achievements.
---
Options Prices
Currently, No data available
---
Ownership Overview
43.49% Insiders
1.25% Mutual Funds
22.66% Other Institutional Investors
31.55% Public Companies and
Individual Investors
8QQ FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was €2.16 and its highest was €5.43 in the past 12 months.
What is AbCellera Biologics’s market cap?
Currently, no data Available
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Feb 25, 2025 which is in 94 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Nov 04, 2024. The company reported -€0.16 earnings per share for the quarter, missing the consensus estimate of -€0.117 by -€0.043.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -€0.13.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 295,366,270 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -€0.16 in its last earnings report, missing expectations of -€0.117. Following the earnings report the stock price went down -8.257%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Among the largest hedge funds holding AbCellera Biologics’s share is Baker Bros Advisors LP. It holds AbCellera Biologics’s shares valued at 72M.
---
AbCellera Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.88 (202.35% Upside)
€7.88 (202.35% Upside)
Blogger Sentiment
Bullish
DE:8QQ Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $740.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.69%
12-Months-Change
Fundamentals
Return on Equity
-15.55%
Trailing 12-Months
Asset Growth
-7.89%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
---
8QQ Company Deck
---
8QQ Earnings Call
Q3 2024
0:00 / 0:00
---
8QQ Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
---
8QQ Stock 12 Month Forecast
Average Price Target
€7.88
▲(202.35% Upside)
Technical Analysis
AbCellera Biologics
―
Allogene Therapeutics
―
Immatics
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering 8QQ
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-34.74%
reiterated a buy rating 19 days ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -34.74% per trade.
---